相关实验视频
Updated: May 12, 2026

09:45
Measuring Cardiac Autonomic Nervous System ANS Activity in Children
Published on: April 29, 2013
20.8K
不同代谢指标对肥胖儿童心室逆极化指数的影响:一项病例对照研究
Asmaa A El Sehmawy1, Rasha Abd El Samad Fawaz1, Nadia Ahmed Agiba2
1Pediatrics Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Clinical medicine insights. Endocrinology and diabetes
|February 10, 2025
概括
肥胖儿童表现出长时间的腹腔再极化,由增加的JTc和QTc分散表明,与更高的BMI和胰岛素抵抗有关.
科学领域:
- 儿童心脏病学 儿童心脏病学
- 代谢障碍 代谢障碍 代谢障碍
- 电子生理学 电子生理学
背景情况:
- 肥胖,胰岛素抵抗和脂质失调是影响儿童心室复极化的潜在因素.
- 了解这些影响对于儿科心血管健康至关重要.
研究的目的:
- 调查肥胖儿童与健康对照人群之间的代谢指标和腹腔再极化之间的关系.
- 确定儿童群体中受肥胖和代谢功能障碍影响的特定心电图参数.
主要方法:
- 一项涉及90名儿童 (45名肥胖者,45名正常体重) 的病例控制研究.
- 对12导电心电图 (ECG) 的分析,用于纠正的QT (QTc),QTc分散 (QTcd),JTc分散和TpTe间隔.
- 评估脂质特征,空腹血葡萄糖 (FPG) 和血清胰岛素,以计算胰岛素抵抗的恒温模型评估 (HOMA-IR).
主要成果:
- 肥胖儿童表现出显著更高的甘油三,胆固醇,LDL,禁食胰岛素和HOMA-IR.
- 肥胖儿童的QTcd和JTcd间隔显着更长.
- 在QTcd/JTc分散和腰围,BMI,血压,禁食胰岛素,HOMA-IR和LDL之间发现了积极的相关性.
结论:
- 肥胖儿童表现出增加的JTc和QTc分散,与腰围,BMI和胰岛素抵抗相关.
- 肥胖儿童的心室再极化异常与代谢失调有关.
相关概念视频
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

